Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2006

View Archived Issues

PowderMed's vaccine approach achieves crossprotection for influenza and drifting strains

Nuvo Research acquires fqubed

IDM Pharma completes sale of non-core assets to Pharmexa

Closing of Pain Therapeutics and King's strategic alliance

pSivida completes acquisition of Control Delivery Systems

MAA completed for Genasense plus chemotherapy in malignant melanoma

InterMune completes sale of Infergen to Valeant

Amarin licenses LAX-202 rights for MS fatigue to Multicell Technologies

Anturol completes phase II dose-ranging study

U.S. Navy to receive defense appropriation for Hemopure R&D

Inex shareholders to vote on Targeted Immunotherapy spin-out

FDA clears NT-proBNP test for new risk stratification use

New quinolone antibacterials emerge from Pfizer R&D

sanofi-aventis prepares and tests new histamine H3 receptor antagonists

Preclinical and clinical erythropoietic activity of CNTO-528

Method for diagnosis/prognosis of wound infection claimed in Ethicon patent

Albaconazole superior to fluconazole in phase II vulvovaginal candidiasis trial

New data support Factor Xa inhibition for thromboprophylaxis

Tamoxifen efficacy in breast cancer affected by CYP450 2D6 genotype

Novel HIV integrase inhibitors designed by Bioflexis

Immunosuppressive effects of NK-026680 useful for acute GVHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...